Persistent depression (dysthymia)

Depression that lasts for years can become so familiar that a person mistakes it for their personality. They may continue working or caring for others while feeling persistently low, exhausted or unable to enjoy much. The duration matters, but it does not mean the condition is permanent or that treatment has already failed. Some people have lived with symptoms for a long time without receiving an adequate course of treatment.

Research points to several routes into persistent depression. Family vulnerability, early experiences, anxiety, continuing stress and difficulties that develop during the illness can all contribute. Scientists understand these broad influences better than they understand the precise biological chain that keeps one person's depression going. There is no established chemical shortage, brain scan finding or blood test that explains every case. Review of dysthymia and persistent depressive disorder

What do “dysthymia” and “persistent depression” mean?

The names overlap, but they are not exact alternatives. In the American diagnostic manual, DSM-5-TR, persistent depressive disorder means depressed mood with accompanying symptoms lasting at least two years in adults. This broad category includes both the older condition called dysthymia and some forms of continuing major depression. The World Health Organization's ICD-11 keeps a narrower dysthymic-disorder category: during the initial two years, symptoms must not meet the full requirements for a depressive episode. The American manual removed “dysthymia” from the title precisely because the broader category made the two names misleadingly interchangeable. American Psychiatric Association explanation

This matters when reading treatment claims. Research on a severe major depressive episode that has continued for years does not automatically tell us the best treatment for longstanding symptoms below that threshold. Conversely, an older dysthymia trial may not represent people with severe chronic major depression. The classification disagreement reflects a scientific uncertainty: persistence may be a useful way of grouping people without revealing one separate biological disease. Comparison of the two diagnostic systems

Three questions therefore need to be kept apart. What helped the depression begin? What now keeps it going? What is happening in the brain and body while it continues? An answer to one does not necessarily answer the others. Duration, current severity and resistance to treatment also describe different things. Years of untreated symptoms cannot establish that treatment will be ineffective.

Family vulnerability and early experience

Persistent depression runs in families. In a community study involving 2,615 close relatives, the families of people with chronic depression had more major depression than the families of people whose major depression occurred in separate episodes. The dysthymia group included only 30 people, however, so the detailed estimates were uncertain. Family resemblance can reflect genes, shared circumstances, parental illness and learned ways of relating; this kind of study cannot separate them completely. Family study of chronic depression

Large genetic studies of depression more generally show that inherited vulnerability is spread across many genetic differences, each usually having a small effect. A major study published in 2025 identified hundreds of associations. It did not isolate persistent depressive disorder, so it cannot supply a precise genetic percentage for this condition or explain an individual's symptoms. There is no established distinctive genetic pattern for dysthymia. Large genetic study of depression

Childhood maltreatment is associated with a more difficult depressive course. A review combining 16 studies and 23,544 participants found about 2.3 times the odds of recurrent or persistent depression among people reporting maltreatment; the statistical uncertainty range was roughly 1.8 to 2.9. This concerned depression broadly and combined recurrence with persistence. It is not a personal risk prediction, an absolute probability or proof that maltreatment caused someone's persistent depression. Review of maltreatment and later depressive course

A more directly relevant ten-year study followed 87 adults whose dysthymia began early in life. Difficult childhood relationships, sexual abuse, anxiety and a family history of chronic depression predicted aspects of later symptoms or functioning. Yet participants were already depressed when studied, and they recalled their childhood experiences afterwards. The findings tell us more about subsequent course than about the exact sequence that first caused illness. Ten-year dysthymia follow-up

Adversity is neither required for persistent depression nor guaranteed to produce it. It may influence a person's sense of safety, expectations of relationships or response to stress, sometimes alongside continuing insecurity. Those possibilities deserve attention without turning every case into an assumed trauma story.

How symptoms and circumstances can reinforce each other

Some people are more readily distressed than others. Anxiety, avoidance and continuing pressure can make recovery harder. In a five-year study of 86 people with early-onset dysthymia, chronic stress, anxiety disorders and certain personality features predicted poorer outcomes. But a personality description collected during depression may partly reflect the illness itself or years spent coping with it. It should not be treated as proof of a fixed underlying character. Five-year study of dysthymia

A wider review of 25 studies involving 5,192 people identified earlier onset, longer episodes and family mood-disorder history as recurring markers of chronic depression. Social disconnection, difficult interactions and other mental-health conditions also featured. Many studies measured these things at one point, so the review could identify associations more confidently than it could rank causes. It also counted findings across studies rather than producing a combined estimate of each association's size and precision. Review of risk factors for chronic depression

One useful working explanation is a reinforcing pattern. Low energy reduces activity and contact with other people. Life then offers fewer rewarding experiences. Repeatedly going over distressing thoughts, or avoiding situations that feel demanding, can make re-engagement harder. Financial pressure, conflict or isolation may continue throughout. This is a plausible account for some people, not a proven universal sequence. A process that maintains symptoms now may have played little part in their original onset. Clinical review of persistent depression

That distinction is encouraging: care can address something that keeps symptoms going even when the original cause cannot be reconstructed. Equally, improvement after therapy does not prove that the illness was caused solely by a person's thoughts or behaviour.

What brain and body research can—and cannot—tell us

Brain chemicals are involved, but a simple shortage is unproven

Serotonin and noradrenaline help brain cells communicate and are involved in the action of several antidepressants. Their relevance does not establish that persistent depression begins with too little of either chemical.

An early study compared 22 people with dysthymia and 22 without it. It found a difference in how blood platelets took up serotonin, but another serotonin-related measure did not differ. Blood platelets are not a direct measurement of serotonin levels in the brain. The study therefore cannot support a diagnosis of “low brain serotonin”. Platelet serotonin study

A treatment can help by changing a system without reversing the illness's original cause. Antidepressant benefit is evidence about a useful treatment, not a test proving a chemical-deficiency theory.

Brain networks may change without explaining recovery

Small studies have found differences in networks involved in emotion and internally focused thought. In one dysthymia study, initially involving 41 patients and 25 controls, connections within a network associated with inward attention were stronger in the patient group. Duloxetine moved this measure towards the comparison group's level. However, the network change did not track symptom improvement, and the study did not directly measure repetitive negative thinking. It therefore cannot show that this network caused rumination or that “normalising” it caused recovery. Dysthymia brain-network study

A 2026 analysis of two small antidepressant trials found treatment-related changes in imaging measures sensitive to brain-tissue structure. The researchers suggested that some initial differences might represent the brain's attempts to compensate for symptoms. That remains an interpretation: the measurements can reflect several biological processes, and scans at only two time points cannot establish the full sequence. Brain-tissue study in persistent depression

Such work helps generate explanations to test. It has not produced a scan that diagnoses persistent depressive disorder, identifies an individual's cause or reliably distinguishes dysthymia from other depressive conditions.

Stress hormones and inflammation do not supply a universal explanation

The body's stress-response systems include hormones such as cortisol. They are relevant to mood and stress, but findings vary with the person, clinical state and measurement. A 2026 review of 126 studies of depression broadly found a very small average reduction in responses to active laboratory stress, mainly in cardiovascular measures. It found no clear overall difference in the hormone responses studied. This does not settle questions about resting cortisol or particular subgroups. Taken with the wider uncertainty, it gives no basis for reducing all persistent depression to continuously excessive stress hormones. Review of laboratory stress responses in depression

Immune-system findings are also preliminary. One study measured 27 immune signals in just 12 people with dysthymia, 12 with major depression and 20 controls. It found different patterns, but such a small study cannot establish a general inflammatory cause or a dependable diagnostic test. A blood-marker difference does not demonstrate inflammation in the brain. It might precede symptoms, follow them or reflect another illness or exposure. Immune-marker study

Sleep and the brain's ability to adapt matter, but findings are not specific

The brain can change how its cells and connections work, an ability often called plasticity. A protein called BDNF supports aspects of that activity. In one small study, blood BDNF levels in dysthymia did not differ clearly from controls, whereas the major-depression group had lower levels than the dysthymia group. This warns against simply transferring a proposed major-depression mechanism to dysthymia. It does not prove that every aspect of brain adaptation is unchanged. BDNF comparison study

Sleep disturbance can contribute to daily difficulties and may help sustain depression. Direct sleep-laboratory research in dysthymia is limited. A study of 11 people selected because they had both dysthymia and insomnia found disrupted sleep compared with 11 controls, but no difference in how quickly they entered rapid-eye-movement sleep, the phase often associated with vivid dreams. That selected group cannot stand for everyone with dysthymia. Sleep-laboratory study

Why biological findings remain uncertain

A difference measured after years of depression may be a pre-existing vulnerability, a feature of current symptoms, a consequence of illness or an adaptation to it. Measuring once cannot distinguish those possibilities. Even before-and-after treatment scans may be insufficient if the proposed mechanism and symptoms change together.

Diagnostic mixing adds another problem. In one study comparing persistent with episodic depression, only one of 34 participants in the persistent-depression group had a purely dysthymic presentation. Most had continuing or intermittent major depressive episodes. Calling that a study of “the psychology of dysthymia” would hide an important limitation. Study illustrating diagnostic mixing

Many biological samples contain only a few dozen people, while complex analyses test numerous possible differences. Several papers may also describe the same participants rather than independent confirmations. The five- and ten-year dysthymia follow-ups belong to one continuing research programme. Some studies have commercial funding; the 2026 imaging report disclosed support from medicine manufacturers and stated that they did not direct the study. Such disclosures inform appraisal without automatically invalidating the findings. Selected samples may also underrepresent later-onset illness, substantial physical illness, acute suicidal crises and complicated combinations of conditions. Longitudinal-study report, 2026 imaging report

Choosing treatment for the person in front of us

Assessment should establish current severity, everyday impairment, the presence of a major depressive episode and what treatments have actually been tried. It should consider anxiety, sleep, relationships and continuing circumstances. Physical conditions such as an underactive thyroid, and the effects of substances or medicines, can sometimes contribute to depressive symptoms. Checking those possibilities is different from looking for a biological test for persistent depressive disorder. WHO diagnostic guidance

Medication and structured psychological treatment are the main established options. An antidepressant, focused cognitive behavioural therapy, or a combination may be appropriate, depending on clinical needs and preferences. For narrower dysthymia without a major depressive episode, medication has the stronger direct trial evidence, although either medication or focused therapy is a reasonable option. Therapy should address continuing processes such as avoidance, repetitive negative thinking and relationship difficulties. NICE guidance on chronic depressive symptoms, Review of dysthymia medication trials

Antidepressants can help, including in dysthymia itself

The medication evidence is not confined to severe major depression. A review of 20 studies, 19 mainly involving dysthymia, found that both selective serotonin reuptake inhibitors, usually called SSRIs, and older tricyclic antidepressants improved response rates compared with placebo. The review did not detect a difference in their response rates, while fewer people stopped SSRIs than tricyclics. Many older trials had unclear methods, limiting confidence in fine distinctions. Review of SSRIs and tricyclic antidepressants

A twelve-week trial involving 416 adults with early-onset dysthymia but no current major depressive episode makes the size of benefit easier to picture. About 59 in every 100 receiving sertraline and 64 in every 100 receiving imipramine were rated substantially improved, compared with 44 in every 100 receiving placebo. More people stopped imipramine because of side effects. These were improvement rates, not complete or lasting recovery rates. Sertraline and imipramine trial

For sertraline, the difference was 15 additional responders per 100 treated over twelve weeks—roughly one extra response for every seven people treated in that trial. This is a group average for that comparison, not a promise about any individual.

A larger comparison brought together 45 medication trials with 5,806 participants in its medication-effectiveness analysis, alongside fifteen psychotherapy or combined-treatment trials. Several drugs, including fluoxetine, paroxetine, sertraline and imipramine, performed better than placebo, but sparse comparisons and different patient groups made a simple “best drug” ranking unreliable. A 2023 review also supported SSRIs and medicines acting on both serotonin and noradrenaline, while finding too little recent and maintenance research to establish a new clear winner. Comparative treatment review, Updated medication review

An SSRI is often a reasonable first medicine to discuss because effectiveness and tolerability both matter. Previous benefit, interactions, sexual effects, sedation, weight changes and withdrawal can influence the choice. Someone may need treatment for a substantial period, so the burden of taking it deserves as much attention as average symptom scores. Changes or stopping should be planned with the prescriber.

Psychological treatment should fit a longstanding problem

Cognitive behavioural therapy helps people examine and change patterns that sustain distress. A specialist approach called the Cognitive Behavioural Analysis System of Psychotherapy—usually shortened to CBASP—was developed specifically for chronic depression. It works with concrete social situations, expectations and the consequences of actions, bringing together thinking, behaviour and relationships.

In a trial of 268 medication-free adults with early-onset chronic depression, CBASP did somewhat better than supportive psychotherapy. Participants could receive 32 sessions across 48 weeks. At twenty weeks, the average advantage was about 2.5 points on a 24-item depression scale, a small effect; the statistical uncertainty range was approximately 0.9 to 4.2 points. This supports CBASP as a credible option, while showing why it should not be presented as a dramatic or universal solution. The trial did not establish that everyone with dysthymia needs CBASP or that well-delivered ordinary CBT is inferior. CBASP comparison trial

Nor can a particular therapy yet be reliably selected from a person's trauma history or personality. A 2025 review of 23 studies found that most proposed treatment predictors had been tested only once, often in small analyses. Initial depression severity was the only well-replicated predictor of outcome. A clinically important history is not automatically a validated rule for choosing between therapies. Review of treatment predictors

Combining therapy and medication helps in some circumstances

The strongest positive trial enrolled 681 adults with chronic major depression. It compared the antidepressant nefazodone, CBASP and their combination. In the response analysis of 662 participants, 73% improved with the combination, compared with 48% in each single-treatment group. That means about 25 additional responders per 100—one extra response for every four people treated with the combination in this particular comparison. It does not mean 73% were cured. The result concerns one medicine–therapy pairing in chronic major depression, not every form of persistent low mood. Combined-treatment trial

An analysis of individual participant data from three trials, including 1,036 people, also favoured CBASP plus medication on average for effectiveness and acceptability. However, it drew on a small network of existing trials, rather than a large series of independent confirmations. Participant-level treatment analysis

Another important trial reached a different result. In REVAMP, 491 people whose chronic depression had not fully improved after an initial medication phase continued with carefully managed medication, either alone or with CBASP or supportive psychotherapy. Adding either therapy did not clearly improve the main outcomes over the next twelve weeks. REVAMP trial

A follow-up published online in September 2026 tracked 323 participants for two further years. About 63% met criteria for a major depressive episode during follow-up, with no clear difference between the original groups. Later treatment was ordinary clinical care rather than a fixed experimental programme. The finding therefore concerns the initial short add-on course; it does not show that longer or differently delivered psychotherapy cannot help. Two-year REVAMP follow-up

Starting two treatments together and adding therapy after a partial medication response are different strategies. Pure dysthymia and chronic major depression also differ. For example, a comparative review found an advantage from adding interpersonal psychotherapy to medication in chronic major depression without demonstrating the same advantage in dysthymia. These distinctions explain why combined care deserves particular consideration for more severe chronic major depression, while remaining an option rather than a universal requirement. Comparative review, VA/DoD depression guideline

Keeping improvement going and changing an ineffective plan

Short-term improvement and staying well are separate questions. A review of longer-term treatment specifically for persistent depression included ten studies and 840 participants. In four medication comparisons involving 383 people, depression returned in about 14% continuing antidepressants and 34% receiving placebo. The pooled estimate put the risk with continued medication at 41% of the placebo group's risk, with a statistical uncertainty range of 21–79%. The result favoured medication, but it was no longer statistically clear when the analysis was restricted to studies with a lower risk of biased results. Evidence comparing maintenance therapy and combined care was sparse. Cochrane review of long-term treatment

Guidelines draw partly on broader depression research when recommending continued care after recovery. CANMAT advises antidepressant continuation for six to twelve months after remission, and two years or longer for people with higher recurrence risk. These are general depression recommendations, not a proven optimal duration for pure dysthymia. Benefit, remaining symptoms and adverse effects need periodic review; treatment should not simply continue indefinitely because the original symptoms were longstanding. CANMAT depression guideline

If improvement is limited, clinicians can reconsider the diagnosis, other illnesses, treatment delivery and practical obstacles, then discuss a different medicine, another psychological treatment or specialist advice. Brain stimulation, electroconvulsive therapy and ketamine-based treatments have roles in selected severe or treatment-resistant major depression. They have not been established as the best starting treatments for uncomplicated dysthymia. Persistent depression accompanied by severe major depression may appropriately enter those specialist pathways. VA/DoD depression guideline

Exercise can be a useful component, supported by depression research more broadly. A 2026 Cochrane review found symptom benefits but uncertainty about study quality and lasting effects. It did not show a specific advantage for persistent depression over medication or therapy. Cochrane exercise review

Social and practical support also matter. Help rebuilding social contact, returning to activities or work, and addressing isolation can accompany clinical treatment. If a long-term medicine has not helped, its benefits and burdens should be reviewed with the prescriber and alternatives discussed, including a supervised change or discontinuation where appropriate. NICE chronic-depression recommendations

What better research needs to resolve

The treatment literature contains useful evidence, but much of it is old and mixes different forms of persistent depression. NICE judged almost all the outcomes in its chronic-depression evidence review to have low or very low certainty. Therapists and patients usually know which psychological treatment they receive; medication side effects can also reveal treatment allocation. Expectations, missing follow-up information, selective reporting and changing treatment during long follow-up complicate comparisons. Several reviews reuse the same trials. A statistically unclear difference does not prove treatments are identical, and stopping treatment is an incomplete measure of how burdensome it was. NICE evidence review

Improvement, remission and functioning must remain distinct. Someone can improve greatly while still struggling, or cease meeting diagnostic criteria while needing help to rebuild relationships and daily life. Studies should measure those outcomes, adverse effects and treatment burden over several years, distinguish withdrawal from recurrence, and test treatment-matching ideas in independent samples.

Research beginning before illness could separate risks for first onset from risks for persistence. Larger biological studies should distinguish narrower dysthymia from chronic major depression, account for current severity and treatment, and test proposed markers in new participants. The most useful mechanism experiments would show that changing a process comes before, and helps explain, later improvement.

Longitudinal research already documents both recovery and relapse, and movement between different chronic-depression patterns. A ten-year study found that the broad distinction between chronic and nonchronic courses was relatively stable, even though people could move between forms of chronic depression after recovery and relapse. Recording duration is therefore clinically useful without implying one separate molecular disease. Persistence is an important part of a person's history; it does not determine the rest of it. Care can begin with a clear account of present difficulties, an acceptable treatment, attention to circumstances and a plan to review what actually changes. Ten-year study of the course of dysthymia